IRCT20190412043247N2
Not Yet Recruiting
Phase 4
The assessment of Empagliflozin Effects in diabetic patients with coronary artery disease: The EMPA-CARD Randomized Clinical Trial
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Zanjan University of Medical Sciences
- Enrollment
- 100
- Status
- Not Yet Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age between 40\-75 year\-old
- •HbA1c between 6\.5 to 9
- •Diabetes mellitus type 2
- •Under fix continues anti\-diabetic treatment for at least 3 month
- •BMI less than 40
- •Fixed Diet and physical activity
- •Resting heart rate between 60 to 100 b/min
- •Use of Aspirin 80 mg/Daily for at least 3 month prior to the beginning of study
- •Glomerular filtration rate (GFR)\>45
- •Documented known Coronary Artery Disease
Exclusion Criteria
- •Heart Failure (NYHA class 3\-4\), Ejection Fraction \<40%
- •History of allergic reaction to SGLT2 inhibitors Drugs
- •History of SGLT2 inhibitor Drugs usage
- •Gastrointestinal malabsorbtion disease
- •History of CABG, ACS, TIA,CVA or PCI during past 3 month
- •History or presence of malignancy
- •Anemia (Hb\<10 g/dl)
- •History of heart or lung transplant
- •Major psychiatric disorders
- •History of DKA
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 4
Dapagliflozin in Acute Heart failureIRCT20220529055013N1Public Sector medical University160
Completed
N/A
The potential effect of Dapagliflozin on diabetic macular edemadiabetic macular edema, diabetesJPRN-UMIN000020331Kyoto Prefectural University of Medicine Department of Endocrinology and Metabolism45
Not Yet Recruiting
N/A
Effect of Dapagliflozin for type 2 diabetes mellitus with fatty liverJPRN-UMIN000026549Kagawa prefectural central hospital25
Unknown
Phase 4
The Effects of Empagliflozin on Arterial Wall CharacteristicsVascular StiffnessHypoglycemic AgentsDiabetes ComplicationsDiabetes Mellitus, Type 1NCT03639545University Medical Centre Ljubljana120
Completed
Phase 1
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKDEnd-stage Kidney DiseaseKidney Disease, ChronicDialysisDiabeticNon-diabeticKidney DysfunctionKidney FailureHemodialysisNCT05614115University of Utah62